HRP20241008T1 - Kristalni oblik spoja inhibitora wee1 i njegova uporaba - Google Patents
Kristalni oblik spoja inhibitora wee1 i njegova uporaba Download PDFInfo
- Publication number
- HRP20241008T1 HRP20241008T1 HRP20241008TT HRP20241008T HRP20241008T1 HR P20241008 T1 HRP20241008 T1 HR P20241008T1 HR P20241008T T HRP20241008T T HR P20241008TT HR P20241008 T HRP20241008 T HR P20241008T HR P20241008 T1 HRP20241008 T1 HR P20241008T1
- Authority
- HR
- Croatia
- Prior art keywords
- crystalline form
- pattern
- crystal form
- ray powder
- angles
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 9
- 101000621390 Homo sapiens Wee1-like protein kinase Proteins 0.000 title 1
- 102100023037 Wee1-like protein kinase Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000013078 crystal Substances 0.000 claims 25
- 238000000634 powder X-ray diffraction Methods 0.000 claims 24
- 238000002411 thermogravimetry Methods 0.000 claims 18
- 238000000113 differential scanning calorimetry Methods 0.000 claims 12
- 230000004580 weight loss Effects 0.000 claims 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 6
- 230000001476 alcoholic effect Effects 0.000 claims 2
- 238000002156 mixing Methods 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 101150040313 Wee1 gene Proteins 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 239000012065 filter cake Substances 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910364694 | 2019-04-30 | ||
| PCT/CN2020/088451 WO2020221358A1 (zh) | 2019-04-30 | 2020-04-30 | Wee1抑制剂化合物的晶型及其应用 |
| EP20798924.5A EP3964510B1 (en) | 2019-04-30 | 2020-04-30 | Crystal form of wee1 inhibitor compound and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20241008T1 true HRP20241008T1 (hr) | 2024-11-08 |
Family
ID=73029676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20241008TT HRP20241008T1 (hr) | 2019-04-30 | 2020-04-30 | Kristalni oblik spoja inhibitora wee1 i njegova uporaba |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US12291536B2 (https=) |
| EP (1) | EP3964510B1 (https=) |
| JP (1) | JP7582970B2 (https=) |
| CN (1) | CN113784968B (https=) |
| AU (1) | AU2020266956B2 (https=) |
| BR (1) | BR112021021230A8 (https=) |
| CA (1) | CA3138240C (https=) |
| DK (1) | DK3964510T3 (https=) |
| ES (1) | ES2984617T3 (https=) |
| FI (1) | FI3964510T3 (https=) |
| HR (1) | HRP20241008T1 (https=) |
| HU (1) | HUE068061T2 (https=) |
| IL (1) | IL287472A (https=) |
| LT (1) | LT3964510T (https=) |
| PL (1) | PL3964510T3 (https=) |
| PT (1) | PT3964510T (https=) |
| RS (1) | RS65747B1 (https=) |
| SG (1) | SG11202111315XA (https=) |
| SI (1) | SI3964510T1 (https=) |
| SM (1) | SMT202400303T1 (https=) |
| WO (1) | WO2020221358A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023217201A2 (zh) * | 2022-05-10 | 2023-11-16 | 杭州德睿智药科技有限公司 | 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7163939B2 (en) * | 2003-11-05 | 2007-01-16 | Abbott Laboratories | Macrocyclic kinase inhibitors |
| PE20080695A1 (es) | 2006-04-27 | 2008-06-28 | Banyu Pharma Co Ltd | Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel |
| CA2667345C (en) * | 2006-10-27 | 2016-03-22 | Signal Pharmaceuticals, Llc | Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and uses therewith |
| JP5411847B2 (ja) * | 2007-04-25 | 2014-02-12 | Ｍｓｄ株式会社 | Ｗｅｅｌキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形 |
| WO2009054332A1 (ja) | 2007-10-23 | 2009-04-30 | Banyu Pharmaceutical Co., Ltd. | ピリドン置換ジヒドロピラゾロピリミジノン誘導体 |
| EP2477628B1 (en) | 2009-09-15 | 2014-08-20 | Merck Sharp & Dohme Corp. | Preparation of crystalline hemihydrate forms of dihydropyrazolopyrimidinone |
| TWI532742B (zh) | 2011-02-28 | 2016-05-11 | 艾伯維有限公司 | 激酶之三環抑制劑 |
| WO2013012681A1 (en) | 2011-07-15 | 2013-01-24 | Abbott Laboratories | Tricyclic inhibitors of kinases useful for the treatment of proliferative diseases |
| US8796289B2 (en) | 2011-07-19 | 2014-08-05 | Abbvie Inc. | Pyridazino[4,5-D]pyrimidin-5(6H)-one inhibitors of kinases |
| US9181239B2 (en) | 2011-10-20 | 2015-11-10 | Abbvie Inc. | Pyridopyrimidinone inhibitors of kinases |
| MX2014010176A (es) | 2012-02-23 | 2014-11-10 | Abbvie Inc | Inhibidores de cinasas de piridopirimidinona. |
| GB201306610D0 (en) | 2013-04-11 | 2013-05-29 | Almac Discovery Ltd | Pharmaceutical compounds |
| WO2015019037A1 (en) | 2013-08-05 | 2015-02-12 | Almac Discovery Limited | Pharmaceutical compounds |
| GB201322602D0 (en) | 2013-12-19 | 2014-02-05 | Almac Discovery Ltd | Pharmaceutical compounds |
| JP6692423B2 (ja) | 2015-11-01 | 2020-05-13 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト | Ｗｅｅ１キナーゼ阻害剤、並びにそれを作製及び使用する方法 |
| US11248006B2 (en) | 2017-03-23 | 2022-02-15 | Shanghai De Novo Pharmatech Co., Ltd. | Macrocyclic derivative of pyrazol[3,4-d]pyrimidin-3-one, pharmaceutical composition and use thereof |
| SG11202003974XA (en) * | 2017-11-01 | 2020-05-28 | Shijiazhuang Sagacity New Drug Development Co Ltd | Macrocyclic compound serving as weel inhibitor and applications thereof |
| US12180184B2 (en) | 2018-10-26 | 2024-12-31 | Wuxi Biocity Biopharmaceutics Co., Ltd. | Pyrimidopyrazolone derivative as Wee1 inhibitor and use thereof |
-
2020
- 2020-04-30 SI SI202030468T patent/SI3964510T1/sl unknown
- 2020-04-30 US US17/607,447 patent/US12291536B2/en active Active
- 2020-04-30 WO PCT/CN2020/088451 patent/WO2020221358A1/zh not_active Ceased
- 2020-04-30 AU AU2020266956A patent/AU2020266956B2/en active Active
- 2020-04-30 HR HRP20241008TT patent/HRP20241008T1/hr unknown
- 2020-04-30 CN CN202080031816.4A patent/CN113784968B/zh active Active
- 2020-04-30 PT PT207989245T patent/PT3964510T/pt unknown
- 2020-04-30 EP EP20798924.5A patent/EP3964510B1/en active Active
- 2020-04-30 PL PL20798924.5T patent/PL3964510T3/pl unknown
- 2020-04-30 SM SM20240303T patent/SMT202400303T1/it unknown
- 2020-04-30 FI FIEP20798924.5T patent/FI3964510T3/fi active
- 2020-04-30 ES ES20798924T patent/ES2984617T3/es active Active
- 2020-04-30 JP JP2021564588A patent/JP7582970B2/ja active Active
- 2020-04-30 DK DK20798924.5T patent/DK3964510T3/da active
- 2020-04-30 BR BR112021021230A patent/BR112021021230A8/pt unknown
- 2020-04-30 CA CA3138240A patent/CA3138240C/en active Active
- 2020-04-30 HU HUE20798924A patent/HUE068061T2/hu unknown
- 2020-04-30 LT LTEPPCT/CN2020/088451T patent/LT3964510T/lt unknown
- 2020-04-30 SG SG11202111315XA patent/SG11202111315XA/en unknown
- 2020-04-30 RS RS20240816A patent/RS65747B1/sr unknown
-
2021
- 2021-10-21 IL IL287472A patent/IL287472A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2984617T3 (es) | 2024-10-30 |
| SG11202111315XA (en) | 2021-11-29 |
| CA3138240C (en) | 2025-04-01 |
| BR112021021230A2 (https=) | 2021-12-21 |
| RS65747B1 (sr) | 2024-08-30 |
| US12291536B2 (en) | 2025-05-06 |
| SI3964510T1 (sl) | 2024-10-30 |
| BR112021021230A8 (pt) | 2023-04-25 |
| IL287472A (en) | 2021-12-01 |
| PT3964510T (pt) | 2024-07-29 |
| AU2020266956B2 (en) | 2025-05-08 |
| CN113784968A (zh) | 2021-12-10 |
| PL3964510T3 (pl) | 2024-08-19 |
| CN113784968B (zh) | 2024-03-15 |
| JP2022530812A (ja) | 2022-07-01 |
| HUE068061T2 (hu) | 2024-12-28 |
| SMT202400303T1 (it) | 2024-09-16 |
| EP3964510A1 (en) | 2022-03-09 |
| FI3964510T3 (fi) | 2024-07-24 |
| EP3964510B1 (en) | 2024-07-03 |
| EP3964510A4 (en) | 2023-04-26 |
| JP7582970B2 (ja) | 2024-11-13 |
| US20220220120A1 (en) | 2022-07-14 |
| AU2020266956A1 (en) | 2021-10-28 |
| DK3964510T3 (da) | 2024-07-29 |
| CA3138240A1 (en) | 2020-11-05 |
| WO2020221358A1 (zh) | 2020-11-05 |
| LT3964510T (lt) | 2024-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20241008T1 (hr) | Kristalni oblik spoja inhibitora wee1 i njegova uporaba | |
| Rana et al. | Site-selective multicomponent synthesis of densely substituted 2-oxo dihydropyrroles catalyzed by clean, reusable, and heterogeneous TiO2 nanopowder | |
| WO2009104021A2 (en) | Novel polymorphs and processes for their preparation | |
| CA2973853C (en) | Novel crystalline forms of neratinib maleate and process of preparation thereof | |
| HRP20240695T1 (hr) | Novi polimorfi kalcijeve soli kao protuupalna, imunomodulatorna i anti-proliferacijska sredstva | |
| HRP20201644T1 (hr) | Kristalni oblik 2-butoksi-7-(4-(pirolidin-1-ilmetil)benzil)-5h-pirolo [3,2-d]pirimidin-4-amina kao agonist tlr7, postupak njegove proizvodnje i njegova uporaba | |
| JP2019505533A5 (https=) | ||
| JP2019504103A5 (https=) | ||
| RU2016101132A (ru) | НАТРИЕВАЯ СОЛЬ 5-БРОМ-2-(α-ГИДРОКСИПЕНТИЛ)БЕНЗОЙНОЙ КИСЛОТЫ В РАЗЛИЧНЫХ КРИСТАЛЛИЧЕСКИХ ФОРМАХ И СПОСОБЫ ЕЕ ПОЛУЧЕНИЯ | |
| JP2022533433A5 (https=) | ||
| JP2011515421A5 (https=) | ||
| DE1939759A1 (de) | Verfahren zur Herstellung von Cyclopropylamin | |
| KR20180113822A (ko) | 1-[(4-메틸-퀴나졸린-2-일)메틸]-3-메틸-7-(2-부틴-1-일)-8-(3-(r)-아미노-피페리딘-1-일)-크산틴의 신규한 결정형 및 그의 제조방법 | |
| RU2020114890A (ru) | Кристаллическое промежуточное соединение, используемое для получения линаглиптина, и способ получения линаглиптина | |
| CN104086436A (zh) | 一种星形四季铵盐的合成方法 | |
| JP2019500385A5 (https=) | ||
| CN103896866A (zh) | 一种制备利奈唑胺晶型i的方法 | |
| CN105418482A (zh) | 一种改进的盐酸罗匹尼罗的制备方法 | |
| JP6040079B2 (ja) | アミド誘導体の製造方法 | |
| US7399871B2 (en) | Crystal forms of (S)-(+)-N,N-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine oxalate and the preparation thereof | |
| CN103408544A (zh) | 一种黄藤素的制备方法 | |
| CN103396370B (zh) | 一种安立生坦的纯化方法 | |
| CN114746431A (zh) | 一种lrrk2抑制剂的晶型及其制备方法 | |
| CN111233927B (zh) | 硫胺类化合物、制备方法及其药物组合物 | |
| CN105503561B (zh) | 一种酸碱指示剂及其合成方法与应用 |